IBM Watson Health & Pfizer:
Accelerating Immuno-Oncology Research with Watson for Drug Discovery

IBM Watson Health and Barrow:
Focused research, faster progress in the fight against ALS

Watson for Drug Discovery is helping researchers at Barrow Neurological Institute identify new targets for ALS research.

Shahram Ebadollahi, VP Innovations and Chief Scientific Officer at Watson Health, and Bob Abraham, Senior VP and Head of Oncology R&D at Pfizer, discuss the importance of this collaboration and the promise of Watson for Drug Discovery's cognitive capabilities to help Pfizer bring promising new immuno-oncology therapeutics to patients more quickly.

In collaboration with the Barrow Neurological Institute, Dr. Robert Bowser and his team of researchers used Watson for Drug Discovery to help identify new targets for ALS research.

IBM Watson for Drug Discovery

Watson for Drug Discovery helps researchers identify novel drug targets and new indications for existing drugs. The platform can help researchers uncover new connections rapidly, which may lead to new insights and scientific breakthroughs.

Read select peer reviewed publications:

Barrow Neurological Institute applied cognitive computing with IBM’s Watson for Drug Discovery to identify 5 novel RNA binding proteins altered in ALS. From nearly 1,500 candidate proteins, Watson helped predict those most likely to be involved in the disease.

Download the paper (49KB)

Watson can accelerate identification of novel drug candidates and novel drug targets by harnessing the potential of big data.

Download the article (584KB)

"We used IBM Watson for Drug Discovery to identify candidates for drug repurposing for L-Dopa-induced dyskinesia in Parkinson’s disease. Preliminary results from animal models indicate early promise of these novel therapies."

Download the poster presentation (1.7MB)

Watson for Drug Discovery uses the KnIT technology and approach to automatically generate hypotheses from scientific literature and patents.

Download the article (2.2MB)

The end-to-end scalable solution offers unique cognitive core capabilities:

Scalable knowledge

IBM Watson for Drug Discovery has the ability to synthesize massive public and private datasets in both tabular and unstructured formats. Natural language processing enables the platform to read millions of pages of unstructured data and understand the nouns, relevant entities, interrelating verbs, and prepositions to comprehend contextual meaning. Healthcare and research language is optimized through training with domain-specific dictionaries, ontologies, and subject matter experts. Professionals can then look across content sources to unearth insights at a scale and speed beyond what is manually possible.

Predictive analytics

Predictive Analytics leverages machine learning to evaluate and learn through reasoning algorithms. Watson can read and understand a massive array of data, including scientific articles, patents, clinical trial data, electronic lab notes, toxicology reports and other proprietary data. Watson’s cognitive capabilities can eliminate bias and detect orthogonal connections and patterns that researchers may not necessarily see to generate novel hypotheses to predict potential relationships for further evaluation.

Dynamic visualization

Dynamic visualizations surface interactive relationships that may be buried in millions of pages of content, giving researchers the ability to:

  • See hidden connections
  • Identify entities with common properties of interest
  • Interact with visualizations by adding and layering different entities
  • Explore relationships on various levels and views
  • Drill down to supporting evidence

Reach out today to find out how Watson for Drug Discovery may help accelerate your scientific breakthroughs.

The latest from Watson Health